Y-mAbs is a commercial-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. We have a broad and advanced product pipeline, including pivotal-stage product candidates against a range of targets. Our mission is to become the world leader in developing better and safer antibody-based oncology products addressing clear unmet pediatric and adult medical needs. With the right partnerships and collaborations, we envision changing the course of cancer care and its outcomes.
我们正在追踪 Y-mAbs Therapeutics, Inc. 的市场扩张
最近 90 天内有 6 个信号。
Y-mAbs Therapeutics, Inc. 的国际扩张与竞争对手的对比情况
Y-mAbs Therapeutics, Inc.你条形图显示所对比公司之间的相对规模。
列5| 公司 | 市场 | 新市场 | 势头 | 活动 | 扩张评分 |
|---|---|---|---|---|---|
 Y-mAbs Therapeutics, Inc.你 | 0 | 0 | — | 0 | 0 |
Senior Director / Director, Medical (Oncology)
查看职位Copenhagen, Capital Region of Denmark, Denmark · 11个月前
Senior Manager / Associate Director, GMP Global QA
查看职位Hørsholm, Capital Region of Denmark, Denmark · 11个月前
Finance Manager
查看职位Hørsholm, Capital Region of Denmark, Denmark · 去年
没有进行中的营销活动
注册以跟踪该公司，并在发生变化时第一时间获得提醒。
Telix Pharmaceuticals任命David Gill为非执行董事,于2026年5月11日生效,计划让他担任主席。Gill拥有超过35年生命科学经验。
解锁已验证邮箱与直拨电话
免费 · 无需信用卡
关于 Y-mAbs Therapeutics, Inc. 的业务、市场和增长信号的快速解答。
